Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 350 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lower protein Clear all
Completed Phase 4 Interventional Results available

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System

NCT02159521
View directory record Official record
Conditions
Deep Vein Thrombosis, Post-thrombotic Syndrome
Interventions
EkoSonic® Endovascular System, Alteplase
Device · Biological
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
Los Angeles, California • Aurora, Colorado • Darien, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accelerating Post-exercise Muscle Glycogen Resynthesis in Humans: Impact of Combined Nutrient Intake and Intermittent Pneumatic Compression or Heat Therapy

NCT04371237
View directory record Official record
Conditions
Muscle Recovery, Muscle Soreness, Glycogen Depletion
Interventions
Compression sleeve, Heat therapy, Glycogen-depleting exercise session, Nutrient Intake (beverage), Skeletal muscle biopsy
Device · Other · Procedure
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

NCT02969356
View directory record Official record
Conditions
Spastic Hemiparesis
Interventions
Botulinum toxin type A, GSC
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 10, 2026, 4:28 AM EDT
Recruiting Phase 1 Interventional

Topical Insulin for Glaucoma

NCT05206877
View directory record Official record
Conditions
Glaucoma
Interventions
Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Protein Requirement of Elderly Men and Women

NCT00812500
View directory record Official record
Conditions
Age
Interventions
Lower Protein, Medium Protein, Higher Protein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

NCT01460498
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults

NCT01489930
View directory record Official record
Conditions
Sarcopenia
Interventions
Endurance exercise, Resistance exercise, Control/Combined training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2011 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
117
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Biobehavioral Impact of Diet Quality on Affect and Craving

NCT04105712
View directory record Official record
Conditions
Food Addiction, Withdrawal
Interventions
Dietary Change (low in highly processed foods)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 40 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

NCT06439485
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Fusion
Interventions
Pemigatinib, Atezolizumab, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 10, 2026, 4:28 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Heat, Microvascular Function and Aging

NCT06633198
View directory record Official record
Conditions
Aging
Interventions
Passive Heating, L-NAME
Procedure · Drug
Lead sponsor
William Hughes
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Patients With Intermittent Claudication Injected With ALDH Bright Cells

NCT01774097
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication
Interventions
ALD-301, Placebo (vehicle)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 10, 2026, 4:28 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Completed No phase listed Observational

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

NCT03017729
View directory record Official record
Conditions
Lower Limb Spasticity
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Washington D.C., District of Columbia • Miami, Florida • North Palm Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 10, 2026, 4:28 AM EDT
Recruiting Phase 2 Interventional

Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

NCT07801664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Deprivation Therapy (ADT), Radiotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation

NCT00646763
View directory record Official record
Conditions
Cytokines
Interventions
G-CSF, GM-CSF administered at extremities, G-CSF and GMCSF administered at abdomen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 10, 2026, 4:28 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

NCT04644185
View directory record Official record
Conditions
Covid19
Interventions
SCTA01, Placebo
Drug · Other
Lead sponsor
Sinocelltech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 10, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

NCT03298087
View directory record Official record
Conditions
Newly Diagnosed Oligometastatic Prostate Cancer
Interventions
radical prostatectomy, stereotactic body radiotherapy, Leuprolide, apalutamide, abiraterone
Procedure · Radiation · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Long Beach, California • West Los Angeles, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 10, 2026, 4:28 AM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 10, 2026, 4:28 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

PUSH Plus Protein Pilot for Hip Fracture Patients

NCT03410823
View directory record Official record
Conditions
Hip Fracture
Interventions
PUSH, Protein, Nutrition
Behavioral · Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 10, 2026, 4:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Smart Underwear to Measure Diet-Induced Hydrogen Sulfide Production

NCT06802276
View directory record Official record
Conditions
Hydrogen Sulfide, Gastrointestinal Microbiome
Interventions
High Cysteine Diet, Low Cysteine Diet
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 4:28 AM EDT
Active, not recruiting Phase 2 Interventional

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

NCT03563248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 10, 2026, 4:28 AM EDT